Advances in surgical approaches to Crohn’s disease: minimally invasive surgery and biologic therapy

References

• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117(4), 761–769 (1999).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn‘s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Radford-Smith G et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial. Gut53(10), 1485–1493 (2004).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Appau KA, Fazio VW, Shen B et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J. Gastrointest. Surg.12(10), 1738–1744 (2008).
   PubMed Web of Science ®Google Scholar
• Sands BE, Kozarek R, Spainhour J et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm. Bowel Dis.13(1), 2–11 (2007).
   PubMed Web of Science ®Google Scholar
• Poggioli G, Stocchi L, Laureti S et al. Duodenal involvement of Crohn’s disease: three different clinicopathologic patterns. Dis. Colon Rectum40(2), 179–183 (1997).
   PubMedGoogle Scholar
• Salky B. Severe gastroduodenal Crohn’s disease: surgical treatment. Inflamm. Bowel Dis.9(2), 129–130 (2003).
   PubMedGoogle Scholar
• Shapiro M, Greenstein AJ, Byrn J et al. Surgical management and outcomes of patients with duodenal Crohn’s disease. J. Am. Coll. Surg.207(1), 36–42 (2008).
   PubMedGoogle Scholar
• Knapp AB, Mirsky FJ, Dillon EH, Korelitz BI. Successful infliximab therapy for a duodenal stricture caused by Crohn’s disease. Inflamm. Bowel Dis.11(12), 1123–1125 (2005).
   PubMedGoogle Scholar
• Odashima M, Otaka M, Jin M et al. Successful treatment of refractory duodenal Crohn’s disease with infliximab. Dig. Dis. Sci.52(1), 31–32 (2007).
   PubMed Web of Science ®Google Scholar
• Rosman AS, Melis M, Fichera A. Metaanalysis of trials comparing laparoscopic and open surgery for Crohn’s disease. Surg. Endosc.19(12), 1549–1555 (2005).
   PubMed Web of Science ®Google Scholar
• Polle SW, Wind J, Ubbink DT, Hommes DW, Gouma DJ, Bemelman WA. Short-term outcomes after laparoscopic ileocolic resection for Crohn’s disease. A systematic review. Dig. Surg.23(5–6), 346–357 (2006).
   PubMedGoogle Scholar
• Tilney HS, Constantinides VA, Heriot AG et al. Comparison of laparoscopic and open ileocecal resection for Crohn’s disease: a metaanalysis. Surg. Endosc.20(7), 1036–1044 (2006).
   PubMed Web of Science ®Google Scholar
• Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn’s disease: a meta-analysis. Dis. Colon Rectum50(5), 576–585 (2007).
   PubMed Web of Science ®Google Scholar
• Dowson HM, Huang A, Soon Y, Gage H, Lovell DP, Rockall TA. Systematic review of the costs of laparoscopic colorectal surgery. Dis. Colon Rectum50(6), 908–919 (2007).
   PubMedGoogle Scholar
• Edden Y, Ciardullo J, Sherafgan K et al. Laparoscopic-assisted ileocolic resection for Crohn’s disease. JSLS12(2), 139–142 (2008).
   PubMedGoogle Scholar
• Holubar SD, Privitera A, Cima RR, Dozois EJ, Pemberton JH, Larson DW. Laparoscopic surgery for recurrent ileocolic Crohn’s disease. Inflamm. Bowel Dis.14(S3), S23 (2008).
   Google Scholar
• Okabayashi K, Hasegawa H, Watanabe M et al. Indications for laparoscopic surgery for Crohn’s disease using the Vienna classification. Colorectal Dis.9(9), 825–829 (2007).
   PubMedGoogle Scholar
• Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm. Bowel Dis.6(1), 8–15 (2000).
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol.19(Suppl. A), 5–36 (2005).
   PubMed Web of Science ®Google Scholar
• Belizon A, Sardinha CT, Sher ME. Converted laparoscopic colectomy: what are the consequences? Surg. Endosc.20(6), 947–951 (2006).
   PubMedGoogle Scholar
• Moorthy K, Shaul T, Foley RJ. Factors that predict conversion in patients undergoing laparoscopic surgery for Crohn’s disease. Am. J. Surg.187(1), 47–51 (2004).
   PubMedGoogle Scholar
• Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis. Colon Rectum50(11), 1968–1986 (2007).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology132(5), 1672–1683 (2007).
   PubMed Web of Science ®Google Scholar
• Holubar SD, Cima RR, Pemberton JH. Does infliximab increase complications after surgery for inflammatory bowel disease? F1000 Med. Reports1(10) (2009).
   PubMedGoogle Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol.99(5), 878–883 (2004).
   PubMed Web of Science ®Google Scholar
• Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J. Gastrointest. Surg.12(10), 1730–1736 (2008).
   PubMed Web of Science ®Google Scholar
• Marchal L, D’Haens G, Van Assche G et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment. Pharmacol. Ther,19(7), 749–754 (2004).
   PubMed Web of Science ®Google Scholar
• Hong D, Lewis M, Tabet J, Anvari M. Prospective comparison of laparoscopic versus open resection for benign colorectal disease. Surg. Laparosc. Endosc. Percutan. Tech.12(4), 238–242 (2002).
   PubMedGoogle Scholar
• Tabet J, Hong D, Kim CW, Wong J, Goodacre R, Anvari M. Laparoscopic versus open bowel resection for Crohn’s disease. Can. J. Gastroenterol.15(4), 237–242 (2001).
   PubMedGoogle Scholar
• Msika S, Iannelli A, Deroide G et al. Can laparoscopy reduce hospital stay in the treatment of Crohn’s disease? Dis. Colon Rectum44(11), 1661–1666 (2001).
   PubMedGoogle Scholar
• da Luz Moreira A, Stocchi L, Remzi FH, Geisler D, Hammel J, Fazio VW. Laparoscopic surgery for patients with Crohn’s colitis: a case-matched study. J. Gastrointest. Surg.11(11), 1529–1533 (2007).
   PubMedGoogle Scholar
• Friedman S, Rubin PH, Bodian C, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn’s colitis: results of a surveillance program spanning 25 years. Clin. Gastroenterol. Hepatol.6(9), 993–998 (2008).
   PubMedGoogle Scholar
• Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn’s colitis: a case–control study. Inflamm. Bowel Dis.12(6), 491–496 (2006).
   PubMed Web of Science ®Google Scholar
• Maykel JA, Hagerman G, Mellgren AF et al. Crohn’s colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis. Colon Rectum49(7), 950–957 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatia JK, Korelitz BI, Panagopoulos G et al. A prospective open-label trial of remicade in patients with severe exacerbation of Crohn’s disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J. Clin. Gastroenterol.41(7), 677–681 (2007).
   PubMedGoogle Scholar
• Ng SC, Kamm MA. Fulminant Crohn’s colitis: when only an antibody will do. Inflamm. Bowel Dis.13(8), 971–974 (2007).
   PubMedGoogle Scholar
• Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn’s colitis. Inflamm. Bowel Dis.14(2), 213–216 (2008).
   PubMed Web of Science ®Google Scholar
• Delaney CP, Fazio VW. Crohn’s disease of the small bowel. Surg. Clin. North Am.81(1), 137–158, ix (2001).
   PubMedGoogle Scholar
• Schwandner O, Schiedeck TH, Bruch HP. Stoma creation for fecal diversion: is the laparoscopic technique appropriate? Int. J. Colorectal Dis.13(5–6), 251–255 (1998).
   PubMedGoogle Scholar
• Ludwig KA, Milsom JW, Church JM, Fazio VW. Preliminary experience with laparoscopic intestinal surgery for Crohn’s disease. Am. J. Surg.171(1), 52–55 (1996).
   PubMedGoogle Scholar
• Loungnarath R, Dietz DW, Mutch MG, Birnbaum EH, Kodner IJ, Fleshman JW. Fibrin glue treatment of complex anal fistulas has low success rate. Dis. Colon Rectum47(4), 432–436 (2004).
   PubMedGoogle Scholar
• Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn’s anal fistulas with fibrin glue injection. Aliment. Pharmacol. Ther.21(12), 1453–1457 (2005).
   PubMedGoogle Scholar
• Lindsey I, Smilgin-Humphreys MM, Cunningham C, Mortensen NJ, George BD. A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Dis. Colon Rectum45(12), 1608–1615 (2002).
   PubMed Web of Science ®Google Scholar
• O’Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME, Armstrong DN. Efficacy of anal fistula plug in closure of Crohn’s anorectal fistulas. Dis. Colon Rectum49(10), 1569–1573 (2006).
   PubMedGoogle Scholar
• Schwandner O, Stadler F, Dietl O, Wirsching RP, Fuerst A. Initial experience on efficacy in closure of cryptoglandular and Crohn’s transsphincteric fistulas by the use of the anal fistula plug. Int. J. Colorectal Dis.23(3), 319–324 (2008).
   PubMedGoogle Scholar
• Ky AJ, Sylla P, Steinhagen R, Steinhagen E, Khaitov S, Ly EK. Collagen fistula plug for the treatment of anal fistulas. Dis. Colon Rectum51(6), 838–843 (2008).
   PubMedGoogle Scholar
• Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis. Colon Rectum46(5), 577–583 (2003).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am. J. Gastroenterol.98(8), 1821–1826 (2003).
   PubMed Web of Science ®Google Scholar
• Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis.7(2), 164–168 (2005).
   PubMed Web of Science ®Google Scholar
• Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis. Colon Rectum49(12), 1837–1841 (2006).
   PubMed Web of Science ®Google Scholar
• Gaertner WB, Decanini A, Mellgren A et al. Does infliximab infusion impact results of operative treatment for Crohn’s perianal fistulas? Dis. Colon. Rectum50(11), 1754–1760 (2007).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm. Bowel Dis.9(2), 98–103 (2003).
   PubMed Web of Science ®Google Scholar
• Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn’s disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases: a pilot study. Scand. J. Gastroenterol.41(9), 1064–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn’s disease. Expert Opin. Biol. Ther.8(9), 1417–1423 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A Phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum48(7), 1416–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Garcia-Arranz M, Garcia LG et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int. J. Colorectal Dis.18(5), 451–454 (2003).
   PubMed Web of Science ®Google Scholar
• Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn’s disease: top-down or step-up? Dig. Dis. (Basel, Switzerland)25(3), 260–266 (2007).
   PubMed Web of Science ®Google Scholar
• Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr. Opin. Gastroenterol.23(4), 395–399 (2007).
   PubMedGoogle Scholar